临床试验:利福昔明对比低FODMAP饮食治疗肠易激综合征
本研究为单盲随机对照试验,将100例成人肠易激综合征患者等比例分配至利福昔明组或低FODMAP饮食组。第4周复合症状改善率两组相似(利福昔明56.0% vs 低FODMAP饮食48.0%,p=0.423),但利福昔明在第2周即显现更早的个体症状改善且治疗依从性更高(95.9% vs 77.8%,p=0.008)。结论认为利福昔明与低FODMAP饮食在4周内疗效相当,但利福昔明起效更快、依从性更好,可作为实用的症状管理选择。
要点
- 利福昔明与低FODMAP饮食第4周复合症状改善率相似。
- 利福昔明第2周整体症状、腹胀和腹痛改善更早。
- 利福昔明治疗依从性显著高于低FODMAP饮食。
核心结论
- 利福昔明治疗肠易激综合征4周疗效与低FODMAP饮食相当。
- 利福昔明症状缓解更快且治疗依从性更高,可作为实用的症状管理替代方案。
研究设计与样本
- 单盲随机对照试验,将100例成人肠易激综合征患者等比例分配至利福昔明组或低FODMAP饮食组。
- 中位年龄50岁,女性占52%,腹泻型肠易激综合征占68%,小肠细菌过度生长占17%。
主要发现
- 第4周复合症状改善率利福昔明56.0% vs 低FODMAP饮食48.0%,p=0.423。
- 第2周整体症状改善率利福昔明90.0% vs 低FODMAP饮食72.0%,p=0.022。
- 第2周腹胀改善率利福昔明84.0% vs 低FODMAP饮食58.0%,p=0.004。
- 第2周腹痛改善率利福昔明80.0% vs 低FODMAP饮食58.0%,p=0.017。
- 小肠细菌过度生长根除率利福昔明63.6% vs 低FODMAP饮食50.0%。
关键数值与推荐
- 主要结局为第4周复合症状改善(腹痛/不适及大便性状/频率)。
- 次要结局包括个体症状改善、IBS症状严重度量表降低≥50分、健康相关生活质量、医院焦虑抑郁量表、小肠细菌过度生长根除、依从性和不良事件。
临床怎么用
- 利福昔明可作为肠易激综合征症状管理的实用选择,尤其需快速缓解症状者。
- 低FODMAP饮食仍为有效选择,但需关注依从性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rifaximin and the low FODMAP diet (LFD) are suggested as second-line therapies for irritable bowel syndrome (IBS). Direct comparative data are limited. AIMS: To compare the efficacy of rifaximin and LFD in IBS. METHODS: In this single-blind, randomised controlled trial, we allocated adults with IBS to rifaximin or LFD. The primary outcome was composite symptom improvement (abdominal pain/discomfort and stool consistency/frequency) at Week 4. Secondary outcomes included individual symptom improvement, ≥ 50 point reduction in IBS Symptom Severity Scale (IBS-SSS), health-related quality of life (HRQOL), Hospital Anxiety and Depression Scale (HADS), small intestinal bacterial overgrowth (SIBO) eradication, adherence and adverse events. RESULTS: We randomised 100 patients equally (median age 50 years; 52% female; 68% IBS-D; 17% SIBO). Based on the composite symptom assessment, response rates were similar between groups (rifaximin 56.0% vs. LFD 48.0%, p = 0.423) at Week 4. However, rifaximin led to significantly earlier individual symptom improvement at Week 2, including global symptoms (90.0% vs. 72.0%, p = 0.022), bloating (84.0% vs. 58.0%, p = 0.004) and abdominal pain (80.0% vs. 58.0%, p = 0.017). HRQOL and anxiety scores improved in both groups. SIBO eradication was observed in 63.6% (rifaximin) and 50.0% (LFD). Adherence was significantly better with rifaximin (95.9% vs. 77.8%, p = 0.008). No serious adverse events occurred. CONCLUSION: Rifaximin is as effective as LFD in treating IBS over 4 weeks. However, it provides faster symptom relief and higher treatment adherence, making it a practical alternative for symptom management. TRIAL REGISTRATION: ClinicalTrials.gov: NCT number: NCT04841980.
引用
- Chuah KH, Loo QY, Loh AJC, et al. Clinical Trial: Rifaximin Versus Low FODMAP Diet in Irritable Bowel Syndrome. Aliment Pharmacol Ther. 2025. PMID: 41098003. doi:10.1111/apt.70420
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。